Literature DB >> 19491908

Connective tissue diseases: New evidence-based guidelines for treating SSc.

Janet E Pope.   

Abstract

A set of recommendations developed by an international panel of experts could have an impact on the care of patients with systemic sclerosis.

Entities:  

Mesh：

Year:  2009        PMID： 19491908     DOI： 10.1038/nrrheum.2009.98

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  9 in total

Review 1.  Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.

Authors:  J Pope; D Fenlon; A Thompson; B Shea; D Furst; G Wells; A Silman
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Musculoskeletal involvement in scleroderma.

Authors:  Janet E Pope
Journal:  Rheum Dis Clin North Am       Date:  2003-05       Impact factor: 2.670

3.  Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.

Authors:  Eric Hachulla; Virginie Gressin; Loïc Guillevin; Patrick Carpentier; Elisabeth Diot; Jean Sibilia; André Kahan; Jean Cabane; Camille Francès; David Launay; Luc Mouthon; Yannick Allanore; Kiet Phong Tiev; Pierre Clerson; Pascal de Groote; Marc Humbert
Journal:  Arthritis Rheum       Date:  2005-12

4.  Scleroderma treatment differs between experts and general rheumatologists.

Authors:  Janet E Pope; Janine M Ouimet; Adriana Krizova
Journal:  Arthritis Rheum       Date:  2006-02-15

Review 5.  The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis.

Authors:  Deanne Malenfant; Michelle Catton; Janet E Pope
Journal:  Rheumatology (Oxford)       Date:  2009-05-11       Impact factor: 7.580

6.  Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.

Authors:  A E Thompson; B Shea; V Welch; D Fenlon; J E Pope
Journal:  Arthritis Rheum       Date:  2001-08

7.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

8.  Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.

Authors:  Sindhu R Johnson; Brian M Feldman; Janet E Pope; George A Tomlinson
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

9.  Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment.

Authors:  Renata Villela; Sai Yan Yuen; Janet E Pope; Murray Baron
Journal:  Arthritis Rheum       Date:  2008-05-15
  9 in total
  1 in total

Review 1.  Targeted therapy for systemic sclerosis: how close are we?

Authors:  Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-Almirall
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.